Discontinuation of long-term adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis.

Breitbach, Marc; Tappeiner, Christoph; Böhm, Michael R R; Zurek-Imhoff, Beatrix; Heinz, Carsten; Thanos, Solon; Ganser, Gerd; Heiligenhaus, Arnd (2017). Discontinuation of long-term adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis. Graefe's archive for clinical and experimental ophthalmology, 255(1), pp. 171-177. Springer 10.1007/s00417-016-3497-5

[img] Text
10.1007_s00417-016-3497-5.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (529kB) | Request a copy

PURPOSE

The purpose of this study was to evaluate the discontinuation of adalimumab (ADA) treatment in patients with juvenile idiopathic arthritis-associated uveitis (JIAU).

METHODS

Patients in whom ADA treatment was initiated for JIAU were included in this retrospective analysis. Reasons for discontinuing ADA treatment in patients with primary treatment response were analysed.

RESULTS

Within a group of 387 JIAU patients, 59 of 68 patients who were treated with ADA achieved a sufficient response to treatment within 6 months. Here, 39 patients (66.1 %) were still on therapy at their last follow-up visit (mean treatment duration of 38.3 months, range 12-91). In another 20 patients, ADA had been discontinued after 1 or 2 years or later, in 10 % (n = 2), 45 % (n = 9) and 45 % (n = 9) of patients, respectively (mean 30.6 months; range 10-65). Reasons for discontinuing ADA were reactivation of uveitis (n = 8, 3.93 per 100 patient-years) or arthritis (n = 4; 1.97 per 100 patient-years), or ≥2 years of complete disease inactivity (n = 3, 1.47 per 100 patient-years), adverse events (n = 4; 1.89 per 100 patient-years), or other (n = 1; 0.47 per 100 patient-years).

CONCLUSIONS

The data show a good primary response to ADA in patients with refractory JIAU. Due to the increasing rate of adalimumab failure or adverse events during long-term treatment, further treatment options may be required.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Tappeiner, Christoph

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0721-832X

Publisher:

Springer

Language:

English

Submitter:

Christoph Tappeiner

Date Deposited:

13 Jul 2017 12:26

Last Modified:

13 Jul 2017 12:26

Publisher DOI:

10.1007/s00417-016-3497-5

PubMed ID:

27687987

Uncontrolled Keywords:

Adalimumab; Biological disease-modifying anti-rheumatic drug; Juvenile idiopathic arthritis; Uveitis

BORIS DOI:

10.7892/boris.93124

URI:

https://boris.unibe.ch/id/eprint/93124

Actions (login required)

Edit item Edit item
Provide Feedback